Eduard Alexander Struys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eduard Alexander Struys has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
C. Jakobs
VU University Medical Centre Clinical Chemistry Metabolic Unit, De Boelelaan 1117 Amsterdam 1081 HV The Netherlands
4 shared publicationsCornelis Jakobs
Metabolic Unit, Department of Clinical Chemistry VU University Medical Center Amsterdam Amsterdam The Netherlands
4 shared publicationsG.S. Salomons
3 shared publicationsK. M. Gibson
Biochemical Genetics Laboratory, Children's Hospital Pittsburgh, Departments of Pediatrics, Pathology and Human Genetics, Division of Medical Genetics University of Pittsburgh School of Medicine Pittsburgh PA USA
3 shared publications- Cornelis Jakobs
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, the Netherlands
2 shared publications - Cornelis Jakobs
Department of Clinical Chemistry, Metabolic Unit, VU Medical Center, Amsterdam; and Divisions of 2Radiology, the Imaging Research Center, and 3Neurology, Children’s Hospital Medical Center, and the University of Cincinnati, Ohio
2 shared publications
Latest Publications
- Open Access
A Missense Variant in ALDH5A1 Associated with Canine Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) in the Saluki Dog
Dogs provide highly valuable models of human disease due to the similarity in phenotype presentation and the ease of genetic analysis. Seven Saluki puppies were investigated for neurological abnormalities including seizures and altered behavior. Magnetic resonance imaging showed a diffuse, marked reduction in cerebral cortical thickness, and symmetrical T2 hyperintensity in specific brain regions. Cerebral cortical atrophy with vacuolation (status spongiosus) was noted on necropsy. Genome-wide association study of 7 affected and 28 normal Salukis revealed a genome-wide significantly associated region on CFA 35. Whole-genome sequencing of three confirmed cases from three different litters revealed a homozygous missense variant within the aldehyde dehydrogenase 5 family member A1 (ALDH5A1) gene (XM_014110599.2: c.866G>A; XP_013966074.2: p.(Gly288Asp). ALDH5A1 encodes a succinic semialdehyde dehydrogenase (SSADH) enzyme critical in the gamma-aminobutyric acid neurotransmitter (GABA) metabolic pathway. Metabolic screening of affected dogs showed markedly elevated gamma-hydroxybutyric acid in serum, cerebrospinal fluid (CSF) and brain, and elevated succinate semialdehyde in urine, CSF and brain. SSADH activity in the brain of affected dogs was low. Affected Saluki dogs had striking similarities to SSADH deficiency in humans although hydroxybutyric aciduria was absent in affected dogs. ALDH5A1-related SSADH deficiency in Salukis provides a unique translational large animal model for the development of novel therapeutic strategies.
Open AccessA Missense Variant in ALDH5A1 Associated with Canine Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) in the Saluki Dog
Dogs provide highly valuable models of human disease due to the similarity in phenotype presentation and the ease of genetic analysis. Seven Saluki puppies were investigated for neurological abnormalities including seizures and altered behavior. Magnetic resonance imaging showed a diffuse, marked reduction in cerebral cortical thickness, and symmetrical T2 hyperintensity in specific brain regions. Cerebral cortical atrophy with vacuolation (status spongiosus) was noted on necropsy. Genome-wide association study of 7 affected and 28 normal Salukis revealed a genome-wide significantly associated region on CFA 35. Whole-genome sequencing of three confirmed cases from three different litters revealed a homozygous missense variant within the aldehyde dehydrogenase 5 family member A1 (ALDH5A1) gene (XM_014110599.2: c.866G>A; XP_013966074.2: p.(Gly288Asp). ALDH5A1 encodes a succinic semialdehyde dehydrogenase (SSADH) enzyme critical in the gamma-aminobutyric acid neurotransmitter (GABA) metabolic pathway. Metabolic screening of affected dogs showed markedly elevated gamma-hydroxybutyric acid in serum, cerebrospinal fluid (CSF) and brain, and elevated succinate semialdehyde in urine, CSF and brain. SSADH activity in the brain of affected dogs was low. Affected Saluki dogs had striking similarities to SSADH deficiency in humans although hydroxybutyric aciduria was absent in affected dogs. ALDH5A1-related SSADH deficiency in Salukis provides a unique translational large animal model for the development of novel therapeutic strategies.
- Open Access
Blood-based metabolic signatures in Alzheimer's disease
Introduction: Identification of blood-based metabolic changes might provide early and easy-to-obtain biomarkers. Methods: We included 127 AD patients and 121 controls with CSF-biomarker-confirmed diagnosis (cut-off tau/A$\beta_{42}$: 0.52). Mass spectrometry platforms determined the concentrations of 53 amine, 22 organic acid, 120 lipid, and 40 oxidative stress compounds. Multiple signatures were assessed: differential expression (nested linear models), classification (logistic regression), and regulatory (network extraction). Results: Twenty-six metabolites were differentially expressed. Metabolites improved the classification performance of clinical variables from 74% to 79%. Network models identified 5 hubs of metabolic dysregulation: Tyrosine, glycylglycine, glutamine, lysophosphatic acid C18:2 and platelet activating factor C16:0. The metabolite network for APOE $\epsilon$4 negative AD patients was less cohesive compared to the network for APOE $\epsilon$4 positive AD patients. Discussion: Multiple signatures point to various promising peripheral markers for further validation. The network differences in AD patients according to APOE genotype may reflect different pathways to AD.
Open AccessBlood-based metabolic signatures in Alzheimer's disease
Introduction: Identification of blood-based metabolic changes might provide early and easy-to-obtain biomarkers. Methods: We included 127 AD patients and 121 controls with CSF-biomarker-confirmed diagnosis (cut-off tau/A$\beta_{42}$: 0.52). Mass spectrometry platforms determined the concentrations of 53 amine, 22 organic acid, 120 lipid, and 40 oxidative stress compounds. Multiple signatures were assessed: differential expression (nested linear models), classification (logistic regression), and regulatory (network extraction). Results: Twenty-six metabolites were differentially expressed. Metabolites improved the classification performance of clinical variables from 74% to 79%. Network models identified 5 hubs of metabolic dysregulation: Tyrosine, glycylglycine, glutamine, lysophosphatic acid C18:2 and platelet activating factor C16:0. The metabolite network for APOE $\epsilon$4 negative AD patients was less cohesive compared to the network for APOE $\epsilon$4 positive AD patients. Discussion: Multiple signatures point to various promising peripheral markers for further validation. The network differences in AD patients according to APOE genotype may reflect different pathways to AD.
- 1 June 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21, e30
Pyridoxine dependent epilepsy: Is late onset a predictor for favorable outcome?
- 1 June 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21, e30
Pyridoxine dependent epilepsy: Is late onset a predictor for favorable outcome?
- 1 June 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21, e124
Pyridoxine-dependent epilepsy (PDE): Diagnostic and therapeutic queries
- 1 June 2017
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 21, e124
Pyridoxine-dependent epilepsy (PDE): Diagnostic and therapeutic queries
- Open Access
- 1 March 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 6, 60-63
Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation
- 1 March 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 6, 60-63
Open AccessPyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation
- 16 January 2014
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (3) , 327-332
Human pyrroline‐5‐carboxylate reductase (PYCR1) acts on Δ1‐piperideine‐6‐carboxylate generating L‐pipecolic acid
We have conducted biochemical studies with commercial available pyrroline‐5‐carboxylate (P5C) reductase (PYCR1) to investigate whether this enzyme plays a role in L‐lysine degradation. Our recent studies with antiquitin/ALDH7A1 deficient fibroblasts revealed an alternative genesis of L‐pipecolic acid, and we then hypothesized that PYCR1 was responsible for the conversion of Δ1‐piperideine‐6‐carboxylate (P6C) into pipecolic acid. We here present evidence that PYCR1 is indeed able to produce L‐pipecolic acid from P6C preparations, and the observed Km for this conversion is of the same magnitude as the Km described for the conversion of P5C to L‐proline by PYCR1. Urine samples from antiquitin deficient individuals, who accumulate P6C, were also incubated with PYCR1 which resulted in a marked decrease of P6C and a huge increase of L‐pipecolic acid as measured by LC‐MS/MS, confirming that indeed PYCR1 generates L‐pipecolic acid from P6C.
- 16 January 2014
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (3) , 327-332
Human pyrroline‐5‐carboxylate reductase (PYCR1) acts on Δ1‐piperideine‐6‐carboxylate generating L‐pipecolic acid
We have conducted biochemical studies with commercial available pyrroline‐5‐carboxylate (P5C) reductase (PYCR1) to investigate whether this enzyme plays a role in L‐lysine degradation. Our recent studies with antiquitin/ALDH7A1 deficient fibroblasts revealed an alternative genesis of L‐pipecolic acid, and we then hypothesized that PYCR1 was responsible for the conversion of Δ1‐piperideine‐6‐carboxylate (P6C) into pipecolic acid. We here present evidence that PYCR1 is indeed able to produce L‐pipecolic acid from P6C preparations, and the observed Km for this conversion is of the same magnitude as the Km described for the conversion of P5C to L‐proline by PYCR1. Urine samples from antiquitin deficient individuals, who accumulate P6C, were also incubated with PYCR1 which resulted in a marked decrease of P6C and a huge increase of L‐pipecolic acid as measured by LC‐MS/MS, confirming that indeed PYCR1 generates L‐pipecolic acid from P6C.
- 6 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (51) , E4939
2-Hydroxyglutarate is not a metabolite; d -2-hydroxyglutarate and l -2-hydroxyglutarate are!
- 6 December 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (51) , E4939
2-Hydroxyglutarate is not a metabolite; d -2-hydroxyglutarate and l -2-hydroxyglutarate are!
- 1 December 2012
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 130 (6) , e1716-e1719
Pyridoxine-dependent Epilepsy With Elevated Urinary α-Amino Adipic Semialdehyde in Molybdenum Cofactor Deficiency
α-Amino adipic semialdehyde (α-AASA) accumulates in body fluids from patients with pyridoxine-dependent epilepsy because of mutations in antiquitin (ALDH7A1) and serves as the biomarker for this condition. We have recently found that the urinary excretion of α-AASA was also increased in molybdenum cofactor and sulfite oxidase deficiencies. The seizures in pyridoxine-dependent epilepsy are caused by lowered cerebral levels of pyridoxal-5-phosphate (PLP), the bioactive form of pyridoxine (vitamin B6), which can be corrected by the supplementation of pyridoxine. The nonenzymatic trapping of PLP by the cyclic form of α-AASA is causative for the lowered cerebral PLP levels. We describe 2 siblings with clinically evident pyridoxine-responsive seizures associated with increased urinary excretion of α-AASA. Subsequent metabolic investigations revealed several metabolic abnormities, all indicative for molybdenum cofactor deficiency. Molecular investigations indeed revealed a known homozygous mutation in the MOCS2 gene. Based upon the clinically evident pyridoxine-responsive seizures in these 2 siblings, we recommend considering pyridoxine supplementation to patients affected with molybdenum cofactor or sulfite oxidase deficiencies.
- 1 December 2012
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 130 (6) , e1716-e1719
Pyridoxine-dependent Epilepsy With Elevated Urinary α-Amino Adipic Semialdehyde in Molybdenum Cofactor Deficiency
α-Amino adipic semialdehyde (α-AASA) accumulates in body fluids from patients with pyridoxine-dependent epilepsy because of mutations in antiquitin (ALDH7A1) and serves as the biomarker for this condition. We have recently found that the urinary excretion of α-AASA was also increased in molybdenum cofactor and sulfite oxidase deficiencies. The seizures in pyridoxine-dependent epilepsy are caused by lowered cerebral levels of pyridoxal-5-phosphate (PLP), the bioactive form of pyridoxine (vitamin B6), which can be corrected by the supplementation of pyridoxine. The nonenzymatic trapping of PLP by the cyclic form of α-AASA is causative for the lowered cerebral PLP levels. We describe 2 siblings with clinically evident pyridoxine-responsive seizures associated with increased urinary excretion of α-AASA. Subsequent metabolic investigations revealed several metabolic abnormities, all indicative for molybdenum cofactor deficiency. Molecular investigations indeed revealed a known homozygous mutation in the MOCS2 gene. Based upon the clinically evident pyridoxine-responsive seizures in these 2 siblings, we recommend considering pyridoxine supplementation to patients affected with molybdenum cofactor or sulfite oxidase deficiencies.
- Open Access
- 17 January 2012
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 35 (5) , 909-916
The measurement of urinary Δ1‐piperideine‐6‐carboxylate, the alter ego of α‐aminoadipic semialdehyde, in Antiquitin deficiency
The assessment of urinary α‐aminoadipic semialdehyde (α‐AASA) has become the diagnostic laboratory test for pyridoxine dependent seizures (PDS). α‐AASA is in spontaneous equilibrium with its cyclic form Δ1‐piperideine‐6‐carboxylate (P6C); a molecule with a heterocyclic ring structure. Ongoing diagnostic screening and monitoring revealed that in some individuals with milder ALDH7A1 variants, and patients co‐treated with a lysine restricted diet, α‐AASA was only modestly increased. This prompted us to investigate the diagnostic power and added value of the assessment of urinary P6C compared to α‐AASA. Urine samples were diluted to a creatinine content of 0.1 mmol/L, followed by the addition of 0.01 nmol [2H9]pipecolic acid as internal standard (IS) and 5 μL was injected onto a Waters C18 T3 HPLC column. Chromatography was performed using water/methanol 97/3 (v/v) including 0.03 % formic acid by volume with a flow rate of 150 μL/min and detection was accomplished in the multiple reaction monitoring mode: P6C m/z 128.1 > 82.1; [2H9]pipecolic acid m/z 139.1 > 93.1. Due to the dualistic nature of α‐AASA/P6C, and the lack of a proper internal standard, the method is semi quantitative. The intra‐assay CVs (n = 10) for two urine samples of proven PDS patients with only modest P6C increases were 4.7% and 8.1%, whereas their inter‐assay CVs (n = 10) were 16 and 18% respectively. In all 40 urine samples from 35 individuals with proven PDS, we detected increased levels of P6C. Therefore, we conclude that the diagnostic power of the assessments of urinary P6C and α‐AASA is comparable.
- 17 January 2012
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 35 (5) , 909-916
Open AccessThe measurement of urinary Δ1‐piperideine‐6‐carboxylate, the alter ego of α‐aminoadipic semialdehyde, in Antiquitin deficiency
The assessment of urinary α‐aminoadipic semialdehyde (α‐AASA) has become the diagnostic laboratory test for pyridoxine dependent seizures (PDS). α‐AASA is in spontaneous equilibrium with its cyclic form Δ1‐piperideine‐6‐carboxylate (P6C); a molecule with a heterocyclic ring structure. Ongoing diagnostic screening and monitoring revealed that in some individuals with milder ALDH7A1 variants, and patients co‐treated with a lysine restricted diet, α‐AASA was only modestly increased. This prompted us to investigate the diagnostic power and added value of the assessment of urinary P6C compared to α‐AASA. Urine samples were diluted to a creatinine content of 0.1 mmol/L, followed by the addition of 0.01 nmol [2H9]pipecolic acid as internal standard (IS) and 5 μL was injected onto a Waters C18 T3 HPLC column. Chromatography was performed using water/methanol 97/3 (v/v) including 0.03 % formic acid by volume with a flow rate of 150 μL/min and detection was accomplished in the multiple reaction monitoring mode: P6C m/z 128.1 > 82.1; [2H9]pipecolic acid m/z 139.1 > 93.1. Due to the dualistic nature of α‐AASA/P6C, and the lack of a proper internal standard, the method is semi quantitative. The intra‐assay CVs (n = 10) for two urine samples of proven PDS patients with only modest P6C increases were 4.7% and 8.1%, whereas their inter‐assay CVs (n = 10) were 16 and 18% respectively. In all 40 urine samples from 35 individuals with proven PDS, we detected increased levels of P6C. Therefore, we conclude that the diagnostic power of the assessments of urinary P6C and α‐AASA is comparable.
- 30 November 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1812 (11) , 1380-1384
A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies
- 30 November 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1812 (11) , 1380-1384
A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies